�ٺ���Ƶ

A nationally recognized leader known for innovations in delivering cancer care has stepped into two critical roles at Perlmutter Cancer Center at �ٺ���Ƶ Hospital—Long Island. Emeline M. Aviki, MD, MBA, serves as both a gynecologic oncologist who sees and treats patients across Long Island and as medical director of network integration and strategy for the cancer center.

“Dr. Aviki is not only treating patients across Long Island, including in Mineola and Patchogue, she’s also part of fulfilling our mission to provide world-leading cancer care closer to home,” said Oren Cahlon, MD, senior vice president and deputy chief clinical officer and a professor in the at NYU Grossman School of Medicine. “We are one network, and we’re proud to demonstrate our commitment to patients diagnosed with cancer across Long Island, Brooklyn, and Queens.”

As clinical assistant professor in the at NYU Grossman Long Island School of Medicine, Dr. Aviki specializes in radical cytoreductive surgery, robotic surgery, fertility-sparing surgery, risk-reducing surgery, and prescribing chemotherapy for patients with ovarian, endometrial, cervical, vaginal, and vulvar cancers.

That clinical excellence meets strategy acumen in the new role of medical director of network integration and strategy, where Dr. Aviki works to advance network expansion, integration, and operations. Asked about �ٺ���Ƶ’s vision for cancer services on Long Island, Queens, and Brooklyn, Dr. Aviki said: “Perlmutter Cancer Center has made a series of strategic investments in improving cancer care outcomes for patients who live on Long Island, Brooklyn, and Queens by bringing world-class cancer specialists and innovative programs to those communities. My role is to partner with cancer center leadership and with members of the community to ensure that we deliver on that promise.”

Before joining �ٺ���Ƶ, Dr. Aviki was nationally recognized for innovation in cancer care delivery and was named one of the “40 under 40 in Cancer” by the Association for Value-Based Cancer Care. At Memorial Sloan Kettering Cancer Center, she founded and led the Affordability Working Group, where she and a multidisciplinary team conducted a three-cycle Plan-Do-Study-Act process to develop, test, and implement a program to refer patients who had cancer and who were in financial need to a hospital-based financial assistance program. In short order, resulted in hundreds of thousands of dollars in financial aid reaching the patients in need.

Dr. Aviki also examining how dose-specific packaging of oral agents can inflict unnecessary costs on patients and their families. Dr. Aviki presented the study on lenvatinib, used for treatment of recurrent endometrial cancer, at the Society of Gynecologic Oncology annual meeting. In response, the pharmaceutical company, Eisai US, created an expanded dose-exchange program for all indications and doses of lenvatinib, eliminating the overspending.

Perlmutter Cancer Center at �ٺ���Ƶ Hospital—Long Island is the only National Cancer Institute–designated Comprehensive Cancer Center with a hospital on Long Island. It offers a robust portfolio of , including phase 1a trials. “This means our patients have the ability to participate in novel lifesaving treatments in a way that is accessible, affordable, and convenient. I’m incredibly proud to be part of a cancer center whose expansion into network sites prioritizes quality, innovation, and patient experience in this way,” said Dr. Aviki.

Dr. Aviki received her medical degree and master of business administration from Duke University. She completed an obstetrics and gynecology residency at the Harvard combined program at Massachusetts General Hospital and Brigham and Women’s Hospital, followed by a gynecologic oncology fellowship at Memorial Sloan Kettering Cancer Center. She has written more than 70 articles in research publications and is on the editorial board for the Journal of Clinical Oncology, Oncology Practice. Castle Connolly named her a Rising Star in 2022 and 2023 and in its “Top Doctors” series for the New York metro area in 2022 and 2023.